<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37696608</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Libman-Sacks endocarditis: regression after immunosuppressive and antiplatelet therapy in a patient with newly diagnosed systemic lupus erythematosus and positive antiphospholipid antibodies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e255726</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2023-255726</ELocationID><Abstract><AbstractText>A woman in her 40s went to the hospital due to persistent headaches. On physical examination, a diastolic murmur in the third sternal intercostal space was the only finding. Echocardiograms were performed, revealing moderate aortic regurgitation and heterogeneously echoreflectant masses of variable shape with no independent mobility, mainly located on the ventricular side of the coaptation point of the three aortic cusps. Initially, aortic septic endocarditis was diagnosed, but no evidence of infection was found. Immunology blood tests were then performed, which determined the presence of systemic lupus erythematosus along with positive antiphospholipid antibodies. The diagnosis of Libman-Sacks endocarditis (LSEn) was established. After receiving steroids, hydroxychloroquine and aspirin, the aortic valvular lesions regressed significantly. This suggests that early treatment with anti-inflammatory and antithrombotic medications in the initial phase of LSEn may prevent the progression of valve deterioration.</AbstractText><CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Hai Yen</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0002-3402-9755</Identifier><AffiliationInfo><Affiliation>Vietnam National Heart Institute - Bach Mai Hospital, Hanoi, Viet Nam tranhaiyenvtm@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Cong Linh</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0009-0005-2964-7857</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Tam Anh Hospital, Hanoi, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thi Huyen</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Radiology Center, Bach Mai Hospital, Hanoi, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Tuan Viet</ForeName><Initials>TV</Initials><Identifier Source="ORCID">0000-0003-2620-9841</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Thanh Hoa Province General Hospital, Thanh Hoa, Viet Nam.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004697" MajorTopicYN="Y">Endocarditis, Bacterial</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunology</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Ultrasonography</Keyword><Keyword MajorTopicYN="N">Valvar diseases</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37696608</ArticleId><ArticleId IdType="pmc">PMC10496658</ArticleId><ArticleId IdType="doi">10.1136/bcr-2023-255726</ArticleId><ArticleId IdType="pii">16/9/e255726</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roldan CA, Shively BK, Crawford MH. Valve excrescences: prevalence, evolution and risk for Cardioembolism. J Am Coll Cardiol 1997;30:1308&#x2013;14. 10.1016/s0735-1097(97)00315-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(97)00315-x</ArticleId><ArticleId IdType="pubmed">9350932</ArticleId></ArticleIdList></Reference><Reference><Citation>Libman E, Sacks B. A hitherto Undescribed form of valvular and mural Endocarditis. Arch Intern Med 1924;33:701. 10.1001/archinte.1924.00110300044002</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1924.00110300044002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim AM SM. Libman-sacks Endocarditis. StatPearls Publishing, 2023. Available: https://www.ncbi.nlm.nih.gov/books/NBK532864/</Citation><ArticleIdList><ArticleId IdType="pubmed">30422459</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz CJ, Mankad R, Klarich K, et al. . Antiphospholipid syndrome and the relationship between laboratory assay positivity and prevalence of non-bacterial thrombotic Endocarditis: A retrospective cohort study. J Thromb Haemost 2020;18:1408&#x2013;14. 10.1111/jth.14798</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14798</ArticleId><ArticleId IdType="pubmed">32180317</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain D, Halushka MK. Cardiac pathology of systemic lupus erythematosus. J Clin Pathol 2009;62:584&#x2013;92. 10.1136/jcp.2009.064311</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.2009.064311</ArticleId><ArticleId IdType="pubmed">19561227</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldan CA, Sibbitt WL, Qualls CR, et al. . Libman-sacks Endocarditis and Embolic cerebrovascular disease. JACC Cardiovasc Imaging 2013;6:973&#x2013;83. 10.1016/j.jcmg.2013.04.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2013.04.012</ArticleId><ArticleId IdType="pmc">PMC3941465</ArticleId><ArticleId IdType="pubmed">24029368</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldan CA, Sibbitt WL, Greene ER, et al. . Libman-sacks Endocarditis and associated cerebrovascular disease: the role of medical therapy. PLoS One 2021;16:e0247052. 10.1371/journal.pone.0247052</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247052</ArticleId><ArticleId IdType="pmc">PMC7886205</ArticleId><ArticleId IdType="pubmed">33592060</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldan CA, Tolstrup K, Macias L, et al. . Libman-sacks Endocarditis: detection, characterization, and clinical correlates by three-dimensional Transesophageal echocardiography. J Am Soc Echocardiogr 2015;28:770&#x2013;9. 10.1016/j.echo.2015.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2015.02.011</ArticleId><ArticleId IdType="pmc">PMC4592775</ArticleId><ArticleId IdType="pubmed">25807885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz D, Oates JC, Kamen DL. Antiphospholipid antibodies and heart valve disease in systemic lupus erythematosus. Am J Med Sci 2018;355:293&#x2013;8. 10.1016/j.amjms.2017.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2017.07.007</ArticleId><ArticleId IdType="pmc">PMC5863618</ArticleId><ArticleId IdType="pubmed">29549933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman R, Lethen H, Zunker U, et al. . Rapid appearance of severe mitral regurgitation under high-dosage corticosteroid therapy in a patient with systemic lupus erythematosus. Eur Heart J 1994;15:138&#x2013;9. 10.1093/oxfordjournals.eurheartj.a060367</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.eurheartj.a060367</ArticleId><ArticleId IdType="pubmed">8174575</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojnik M, George J, Ziporen L, et al. . Heart valve involvement (Libman-sacks Endocarditis) in the Antiphospholipid syndrome. Circulation 1996;93:1579&#x2013;87. 10.1161/01.cir.93.8.1579</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.93.8.1579</ArticleId><ArticleId IdType="pubmed">8608627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizu K, Isotani A, Yamaji K, et al. . Immunosuppressive therapy to reduce mitral regurgitation in Libman-sacks Endocarditis: a case report. Eur Heart J Case Rep 2019;3:ytz133. 10.1093/ehjcr/ytz133</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytz133</ArticleId><ArticleId IdType="pmc">PMC6764580</ArticleId><ArticleId IdType="pubmed">31377769</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>